Cancer research continues to progress with promising new treatments and diagnostic tools. Senhwa Biosciences received U.S. NCI sponsorship for a program targeting MYC-aberrant lymphoma, while AbbVie and Genmab’s T cell engager Epkinly advanced following Phase 3 success in follicular lymphoma. Advances also include new biomarkers improving risk stratification in colon cancer and multi-omics approaches clarifying chronic lymphocytic leukemia immunoregulation. The expansion of precision oncology is underscored by growing incorporation of ctDNA for personalized treatment monitoring and emerging nanotechnology-driven drug delivery platforms.